Gold Fields Limited (GFI) Stock Price Today
Aura AI Summary
Key Stats
- $36.85BMarket Cap
- 3,479,612Volume
- Basic MaterialsSector
- $61.5252W High
- $31.2552W Low
- 48 DaysTypical Hold Time
- $37.45BEnterprise Value
- 5.27%Div Yield
- 24% Sell | 76% BuyTrading Activity
Track Gold Fields Limited (GFI) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Gold Fields Limited has traded between a low of $31.25 and a high of $61.52, highlighting its annual price range. Buy and sell Gold Fields Limited shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Most Recent News
General Mills sees 3% sales drop but beats earnings estimates with strong international growth.
General Mills reported a 3% decline in sales to $4.40 billion, partly due to selling its U.S. yogurt business, causing adjusted gross margin to fall to 33.3%. Despite this, the company beat earnings expectations with adjusted EPS of $0.75, helped by ...

High interest rates boost dividends for top property and casualty insurers like Chubb and Travelers.
Four major property and casualty insurers—Chubb, Travelers, Cincinnati Financial, and Allstate—are benefiting from high Treasury yields near five-year highs, which increase investment income from premiums they hold before paying claims. This structur...

Novo Nordisk plans 5+ multi-blockbusters by 2030, with strong Q2 sales growth in Wegovy and rare endocrine drugs.
At its Capital Markets Day on September 21, Novo Nordisk announced ambitious plans to launch more than five multi-blockbuster drugs by 2030 and achieve over DKK 150 billion in pipeline sales by 2035. CEO Maziar Doustdar emphasized prioritizing asset ...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.